王建祥，1963年生，籍贯山东，血液学家，血液病医院（血液学研究所）主任医师，博士生导师。1980年考入山东医学院医学专业，1985年获得学士学位。1988-1991年在中国协和医科大学医学专业攻读硕士学位，从事白血病临床及基础研究，期间在日本熊本大学医学部研修一年。1994-1999年在美国NIH从事白血病发病机制研究。1991年升为主治医师，1994年为副主任医师，1999年为主任医师。2019年任国家血液系统疾病临床医学研究中心主任。

主要从事白血病的临床与基础研究，探究白血病的发病机理、靶向治疗和预后危险度分层治疗，研发具有自主知识产权的抗白血病细胞的嵌合性抗原受体（CAR）及其修饰的T细胞（CAR-T）在白血病治疗中的作用。

1. Yu Zhang#, Saisai Li#, Ying Wang, Yang Lu, Yingxi Xu, Qing Rao, Huijun Wang， Haiyan Xing, Zheng Tian, Kejing Tang, Lulu Lv, Min Wang*, Jianxiang Wang*, A novel and efficient CD22 CAR‑T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR‑T treatment as a sequential therapy, Exp Hematol Oncol, 2022, 11:15. (IF=8.593, 2021)

2. Yingxi Xu#, Junli Mou, Ying Wang, Wei Zhou, Qing Rao, Haiyan Xing, Zheng Tian, Kejing Tang, Min Wang*, Jianxiang Wang*, Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine related signaling pathway, Leukemia, 2022; 36(2): 403-415. (IF=12.897, 2021)

3. Nianci Chen#, Yingxi Xu#, Junli Mou, Qing Rao, Haiyan Xin, Zheng Tian, Kejing Tang, Min Wang*, Jianxiang Wang*, Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells, Blood Cancer J, 2021; 11(8): 144. (IF=9.812)

4. Runxia Gu#, Fang Liu#, Dehui Zou#, Yingxi Xu, Yang Lu, Bingcheng Liu, Wei Liu, Xiaojuan Chen, Kaiqi Liu, Ye Guo, Xiaoyuan Gong, Rui Lv, Xia Chen, Chunlin Zhou, Mengjun Zhong, Huijun Wang, Hui Wei, Yingchang Mi, Lugui Qiu, Lulu Lv, Min Wang, Ying Wang*, Xiaofan Zhu*, Jianxiang Wang*, Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia, J Hematol Oncol, 2020; 13(1): 122. (IF=17.338)

5. Hui Wei#, Ying Wang#, Robert Peter Gale, Dong Lin, Chunlin Zhou, Bingcheng Liu, Shaowei Qiu, Runxia Gu, Yan Li, Xingli Zhao, Shuning Wei, Benfa Gong, Kaiqi Liu, Xiaoyuan Gong, Yuntao Liu, Guangji Zhang, Zhen Song, Yang Wang, Wei Li, Yingchang Mi*, Jianxiang Wang*, Randomized trial of intermediate-dose cytarabine in induction and consolidation therapy in adults with acute myeloid leukaemia, Clin Cancer Res. 2020; 26(13): 3154-3161. (IF=12.531)

6. Li Zhang#, Li Meng#, Bingcheng Liu#, Yanli Zhang, Huanling Zhu, Jiuwei Cui, Aining Sun, Yu Hu, Jie Jin, Hao Jiang, Xi Zhang, Yan Li, Li Liu, Wanggang Zhang, Xiaoli Liu, Jian Gu, Jianhui Qiao, Guifang Ouyang, Xin Liu, Jianmin Luo, Ming Jiang, Xiaobao Xie, Jianyong Li, Chunting Zhao, Mei Zhang, Tonghua Yang, Jianxiang Wang*, Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study, Clin Cancer Res. 2021; 27(1): 70-77. (IF= 13.801)

7. Shuang Liu#, Yanyan Xing#, Wenting Lu, Shouyun Li, Zheng Tian, Haiyan Xing, Kejing Tang, Yingxi Xu, Qing Rao, Min Wang* and Jianxiang Wang*，RUNX1 inhibits proliferation and induces apoptosis of t (8;21) leukemia cells via KLF4 mediated transactivation of P57, Haematologica, 2019; 104 (8):1597-1607. (IF=7.116)

8. Huan Li#, Na Zhao, Yihui Li, Haiyan Xing, Shuying Chen, Yingxi Xu, Kejing Tang, Zheng Tian, Min Wang, Qing Rao*, Jianxiang Wang*, c-MPL is a candidate surface marker and confers self-renewal, quiescence, chemotherapy resistance, and leukemia initiation potential in leukemia stem cells, Stem Cells, 2018; 36:1685–1696. (IF= 5.614)

9. Ying Wang#, Yingxi Xu#, Saisai Li, Jia Liu, Yanyan Xing, Haiyan Xing, Zheng Tian, Kejing Tang, Qing Rao, Min Wang*, Jianxiang Wang*, Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells, J Hematol Oncol. 2018; 11(1): 60. (IF= 8.731)

10. Yirui Chen#, Shouyun Li#, Chunlin Zhou, Chengwen Li, Kun Ru, Qing Rao, Haiyan Xing, Zheng Tian, Kejing Tang, Yingchang Mi, Baohong Wang, Min Wang*, Jianxiang Wang*, TBLR1 fuses to retinoid acid receptor alpha in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia, Blood, 2014, 124(6):936-945. (IF= 10.452)